Payment overview · 2025
General Payments
$295.30
17 reported records · 10 companies
Healthcare provider profile · identity verified
Rupinder Gill, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SCOTTSBURG, IN · NPI 1770565897
Verified facts
What the public records show
CMS Open Payments records show Rupinder Gill, MD received $295.30 in general payments during 2025 across 17 reported records.
GlaxoSmithKline, LLC. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Rexulti, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.61 | 29.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $51.06 | 17.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.29 | 11.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.84 | 7.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.74 | 7.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.84 | 5.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.53 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.82 | 5.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.00 | 4.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.57 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $295.30 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.61 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.06 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 94 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
74 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
134 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
274 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 900 | 232 |
| Gabapentin | Gabapentin | 652 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 569 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 461 | 117 |
| Furosemide | Furosemide | 411 | 99 |
| Potassium Chloride | Potassium Chloride | 368 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 325 | 93 |
| Omeprazole | Omeprazole | 325 | 91 |
| Tramadol Hcl | Tramadol Hcl | 316 | 62 |
| Ozempic | Semaglutide | 274 | 52 |
| Meloxicam | Meloxicam | 245 | 70 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 91 |
| Glimepiride | Glimepiride | 229 | 61 |
| Metformin Hcl | Metformin Hcl | 222 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 219 | 48 |
| Eliquis | Apixaban | 198 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 49 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 182 | 45 |
| Celecoxib | Celecoxib | 180 | 47 |
| Montelukast Sodium | Montelukast Sodium | 177 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 50 |
| Carvedilol | Carvedilol | 163 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 149 | 40 |
| Clonazepam | Clonazepam | 144 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 141 | 58 |
| Mirtazapine | Mirtazapine | 138 | 33 |
| Lisinopril | Lisinopril | 136 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 14 |
| Mounjaro | Tirzepatide | 134 | 30 |
| Losartan Potassium | Losartan Potassium | 128 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 126 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 26 |
| Sertraline Hcl | Sertraline Hcl | 123 | 32 |
| Prednisone | Prednisone | 117 | 59 |
| Donepezil Hcl | Donepezil Hcl | 115 | 19 |
| Buspirone Hcl | Buspirone Hcl | 113 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 113 | 30 |
| Alprazolam | Alprazolam | 112 | 23 |
| Trazodone Hcl | Trazodone Hcl | 111 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 24 |
| Spironolactone | Spironolactone | 110 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 26 |
| Levetiracetam | Levetiracetam | 101 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 33 |
| Jardiance | Empagliflozin | 94 | 27 |
| Allopurinol | Allopurinol | 89 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 23 |
| Azithromycin | Azithromycin | 85 | 61 |
| Doxycycline Hyclate | Doxycycline Hyclate | 84 | 53 |
| Linzess | Linaclotide | 83 | 27 |
| Bumetanide | Bumetanide | 79 | 22 |
| Ondansetron Odt | Ondansetron | 79 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 17 |
| Simvastatin | Simvastatin | 76 | 18 |
| Pregabalin | Pregabalin | 75 | suppressed |
| Baclofen | Baclofen | 74 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 18 |
| Synthroid | Levothyroxine Sodium | 74 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 21 |
| Januvia | Sitagliptin Phosphate | 72 | 22 |
| Fenofibrate | Fenofibrate | 71 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | suppressed |
| Famotidine | Famotidine | 68 | 16 |
| Enalapril Maleate | Enalapril Maleate | 66 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 65 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Risperidone | Risperidone | 63 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 30 |
| Olanzapine | Olanzapine | 62 | 12 |
| Lorazepam | Lorazepam | 61 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 60 | 17 |
| Cephalexin | Cephalexin | 54 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 11 |
| Meclizine Hcl | Meclizine Hcl | 53 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 42 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Midodrine Hcl | Midodrine Hcl | 51 | suppressed |
| Latanoprost | Latanoprost | 49 | suppressed |
| Topiramate | Topiramate | 49 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 47 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 24 |
| Nystatin | Nystatin | 47 | 24 |
| Sucralfate | Sucralfate | 47 | 11 |
| Atenolol | Atenolol | 46 | suppressed |
| Glipizide | Glipizide | 45 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | 11 |
| Mupirocin | Mupirocin | 41 | 27 |
| Lacosamide | Lacosamide | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 29 |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 11 |
| Colestipol Hcl | Colestipol Hcl | 36 | 12 |
| Temazepam | Temazepam | 35 | suppressed |
| Fluconazole | Fluconazole | 34 | 24 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Naproxen | Naproxen | 32 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 32 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 21 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Rexulti | Brexpiprazole | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 18 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 14 |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Azathioprine | Azathioprine | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 11 |
| Tradjenta | Linagliptin | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $295.30 · 17 records | GlaxoSmithKline, LLC. | AIRSUPRA, BREZTRI, Cologuard Collection Kit, JARDIANCE, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error